Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Status:
Completed
Trial end date:
2016-07-15
Target enrollment:
Participant gender:
Summary
This is an international, multi-centre, single arm Bayesian designed phase 2 study to
identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with
relapsed and/or refractory ESFT. Approximately 40 patients will be recruited from 5-7
European centres. Each patient will be treated with single agent linsitinib, 600 mg orally
once a day for days 1-3, 8-10 and 15-17 on a 21 day cycle until disease progression or undue
toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Astellas Pharma Inc European Commission European Organisation for Research and Treatment of Cancer - EORTC Oxford University Hospitals NHS Trust